What is the Fiscal Year for Biomea Fusion?
Date: November 14, 2026
Biomea Fusion's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
San Carlos, California
Industry
Biotechnology Research
Stock Symbol
BMEA
Website
https://biomeafusion.comDescription
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure!
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Biomea Fusion and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.